Life Innovations

Innovative Benchtop Solutions

In the Life organization, we established a business vision of real life innovations: "We will lead the world in advancing Bio Industrial Autonomy and contribute to a future embracing global harmony" with the aim of clarifying future developments of the business, its scope and direction. In this vision, we have targeted the "Pharmaceutical, Food, Beverage & Biotech" sectors and aim to further expand our business, centering on these industries, by taking advantage of our strengths in "Measurement, Imaging, Analysis, Diagnosis, Integration" and Yokogawa core technologies.

 


Life Innovations

Life Science

By contributing to the development of measurement and analysis technologies, we will solve problems that limit research progress and create a world where scientists can concentrate on science.

Bioprocess

Using real-time monitoring and software innovations, we will create a virtual world of "Digital Twin" where experimental simulations are leveraged  to realize precision predictive control

Pharmaceutical

We analyze and control the information obtained from all manufacturing activities and solve issues related to raw material quality, facility degradation, transmission of technology, and production processes to improve work environment and worker safety.

Food&Beverage

In addition to improving optimal and efficient automatic processes based on demand forecasting, we will assist with quality improvements that include taste attributes, and promote autonomous operation that grows independent of human intervention.
 

Water & Wastewater

Yokogawa supports a wide range of water control applications in both the municipal and industrial water markets.

  • Life Science

    We have 30 years of experience in this life science field and will respond to customer's problem solving with cutting-edge solutions.

    See More
  • Solutions for Single-cell Analysis

    YOKOGAWA is working on the development of single cell mass spectrometry and single cell gene analysis.  In order to analyze one cell with high sensitivity, we are developing a method of collecting target cells while keeping position information under observing cells with confocal scanner.

    See More
  • OpreX Environmental Monitoring System

    The OpreX™ Environmental Monitoring System collects, measures, and stores temperature and humidity as well as other management data for comprehensive oversight of the pharmaceutical manufacturing, quality control, and storage areas.

    See More
  • Solutions for Pharmaceutical

    Yokogawa is contributing to the development of the pharmaceutical industry based on its performance of introducing over 1,000 systems in the areas of drug substances, pharmaceutical products, and biotechnology.

    See More
  • Solutions for Food & Beverage

    In addition to daily improvement cycles, Yokogawa will use IIoT to support create environments that do not cause defects and that are designed to completely reduce losses.

    See More

Details

Life Business Headquarters’ contribution towards the fight against Novel Coronavirus Disease (COVID-19)

Yokogawa established the Life Business Headquarters with the goal of promoting well-being for all. In addition to engaging in our existing life science and manufacturing solutions businesses targeting the pharmaceutical and food industries, the headquarters works to develop new products and services and provides one-stop solutions that revolutionize productivity throughout the pharmaceutical and food industry value chain, from basic research to manufacturing, logistics, and services.

Yokogawa has more than 30 years’ experience in the life science field. The CSU spinning disk confocal scanner series is our core strength, and over 3,000 units have been sold globally. Other products, including a live cell imaging system, a high-content analysis system and single cell analysis solution also support leading life science studies. In the field of manufacturing solutions, over 1,000 Yokogawa manufacturing, production, and quality management systems and control systems have been introduced in the pharmaceutical industry.

In response to the novel coronavirus (COVID-19), Yokogawa has been taking various measures to prevent transmission of the virus while working to minimize the impact on customers. We are also contributing to the fight against COVID-19 by collaborating with research institutes globally and supporting research to develop new medication or vaccines. Yokogawa will continue to work with customers and business partners in an effort to resolve the crisis society is facing.

Please contact our sales and service representatives if you have any interest in our products, or you can send inquiries from the form below.

January 8,2021

Sales release : Advanced Control Bioreactor System BR1000 was released.
The Advanced Control Bioreactor System BR1000 automates lab-scale mammalian cell culture with highly accurate real-time monitoring and advanced process control.

Click Here For More Info 

October 23,2020

YOKOGAWA Sponsored Webinar
November 24, 2020 3:00 pm to 4:00 pm JST
(11:30 am to 12:30 pm India/ 2:00 pm to 3:00 pm SGT)

Abstract:
Process control for mammalian cell culture is cutting-edge with Yokogawa’s lab-scale advanced control bioreactor system.
In-line sensing and cell model derivation has never been easier or more accurate.
Driven by innovative model predictive control, the dynamic feeding of glucose results in overall productivity and product quality gains.

Click Here for Registration

August 21,2020

Bioprocessing Summit 2020 Virtual

Dates: August 24-28 EST, 2020
Location: Virtual Event

Yokogawa introduce about advanced automated bioreactor controller system. Join us at our virtual tradeshow booth. We look forward to connecting with you.

Click Here For Registration

August 20,2020

Discovering Potential Covid-19 Therapies using High Content Screening

Date: Wednesday August 26th 2020
Time: 12pm (EST) 9am (PST) 5pm (London)

Abstract:
In this webinar, Professor Jonny Sexton discusses a pipeline, developed in the Sexton lab, for the quantitative high-throughput image-based screening of SARS-CoV-2 infection to identify potential antiviral mechanisms and allow selection of appropriate drug combinations to treat COVID-19. This webinar presents evidence that morphological profiling can robustly identify new potential therapeutics against SARS-CoV-2 infection as well as drugs that potentially worsen COVID-19 outcomes.

Click Here for  Registration

June 22,2020

YOKOGAWA Sponsored Webinar

July 29, 2020 11 am to 12 pm EDT (July 30, 2020 0 am to 1 am JST)

Integration of soft-sensor technologies with CHO-cell predictive models for improved bioreactor automation & process control

Abstract:
Process control for mammalian cell culture is cutting-edge with Yokogawa’s lab-scale advanced control bioreactor system.  In-line sensing and cell model derivation has never been easier or more accurate.  Driven by innovative model predictive control, the dynamic feeding of glucose results in overall productivity and product quality gains.  And the same cell model and automation concept can also be applied to biopharmaceutical product manufacturing.

Click Here for Registration

June 5,2020

BIO Digital 2020

June 8-12, 2020
Virtual Event
Click Here For More Info

We will participate in partnering event and hold a corporate seminar about Advanced Control Bioreactor System.

Yokogawa Life Science Twitter Yokogawa Life Science Facebook Yokogawa Life Science Linkedin Yokogawa Life Sciences YouTube

Resources

Overview:

A critical requirement in biopharmaceutical development is the integration and automation of process equipment and analytical instruments used in the laboratory. Bioprocess labs with multiple lab-scale bioreactors often execute cultivation experiments in parallel for research or process development purposes.

As part of a collaboration between Securecell (Zurich, SW) and Yokogawa Life Science (Tokyo, Japan), this application note demonstrates the effective use of the Lucullus® Process Information Management System (Lucullus®) to assist in the control of three Advanced Control Bioreactor Systems (BR1000) to study glucose utilization of CHO cells for optimal monoclonal antibody productivity.

Industries:
Overview:

Exploring the technologies needed to achieve automatic control of cell culture processes.

Industries:
The external dimensions of the CSU-X1 Confocal Scanner Unit series are as follows: CSU-X1-M1: 175(W) × 328.5(H) × 213.4(L)mm CSU-X1-M2: 259(W) × 373(H) × 213.4(L)mm CSU-X1-M3: 308.5(W) × 328.5(H) × 213.4(L)mm C...

Downloads

Videos

Overview:

In this webinar, Professor Jonny Sexton discusses a pipeline, developed in the Sexton lab, for the quantitative high-throughput image-based screening of SARS-CoV-2 infection to identify potential antiviral mechanisms and allow selection of appropriate drug combinations to treat COVID-19. This webinar presents evidence that morphological profiling can robustly identify new potential therapeutics against SARS-CoV-2 infection as well as drugs that potentially worsen COVID-19 outcomes.

Overview:

Dr. Sexton discusses high content screening for phenotypic-based drug discovery and development using Yokogawa technologies. This webinar presents the methodology behind acquiring good images that are able to leverage the three-dimensionality of different cell systems. His assays include 3D models such as organoids and spheroids.

In this webinar, you will discover:

  • How to identify when 2D or 3D methods are required to achieve desired results.
  • How to leverage your High Content Imaging Systems to get optimal signals and backgrounds.
  • Techniques that are used to improve cell observation yield and statistical distributions of morphological features.
Overview:

Generating translatable high-content imaging data from physiologically-relevant cell models, including 2D and 3D structures, is extremely valuable for drug discovery and pre-clinical research. In this webinar, James Evans, CEO of PhenoVista Biosciences presents case studies on how Yokogawa’s Benchtop CQ1 Confocal System can improve throughput and standardize processes for complex 3D cell-based phenotypic assays.

Key learning objectives:

  • Strategies for designing and implementing high-content screening assays
  • Approaches for deciding between 2D and 3D model systems
Overview:

Human pluripotent stem cells are proven efficient models for drug screening campaigns. They provide access to unlimited starting material amenable to high throughput small molecule compound screening. Due to their capacity to generate mode complex cellular models, they also offer the potential to perform high content screening in tissue-specific organoids for further human target validation.

Dr. Alejandro Hidalgo-Gonzalez at MCRI(Murdoch Children's Research Institute) in Australia is a user of our HCA system CellVoyager CV8000 and he has established a pipeline for assay development and automated unbiased phenotypic drug screening using human pluripotent stem cell-derived cells and organoids. This is a recording of his presentation at an educational webinar organized by A*STAR in Singapore.

Overview:

3D imaging experts from Yokogawa and Insphero have come together to provide helpful tips and tricks on acquiring the best 3D spheroid and organoid imaging. This webinar focuses on sample preparation, imaging, and analysis for both fixed and live cells in High Content Screening assays. The experts also discuss automated tools that can help researchers understand the large volume of data in these High Content Imaging Analysis Systems.

Overview:

3D imaging experts from Yokogawa and Insphero have come together to provide helpful tips and tricks on acquiring the best 3D spheroid and organoid imaging. This webinar focuses on sample preparation, imaging, and analysis for both fixed and live cells in High Content Screening assays. The experts also discuss automated tools that can help researchers understand the large volume of data in these High Content Imaging Analysis Systems.

Overview:

This webinar highlights Yokogawa’s High Content Solutions, the benchtop confocal CellVoyager CQ1, and CellVoyager CV8000. Utilizing Yokogawa’s dual-wide microlens spinning disk confocal technology, these automated HCA systems provide remarkable image quality while increasing your output. This frees up time to complete other research activities. Also, recent additions to the CSU-W1 confocal upgrade is discussed. The SoRa, a super-resolution solution, and the Uniformizer, an image flattening device. Both of which can be added to the lightpath of your CSU-W1-enhanced microscope.

Agenda:
Introduction to Yokogawa
SoRa for CSU-W1 super-resolution with confocal
Two high content instruments from Yokogawa: The CQ1 and the CV8000

Presenter:
Dan J. Collins, Applications Scientist, Yokogawa Life Science

Overview:

In the last few decades, the pharmaceutical industry has transformed people’s lives. However, the development of new drugs is becoming increasingly difficult and a paradigm shift in the drug discovery workflow is required to reduce attrition and transform conventional drug screening assays into translatable analytical techniques for the analysis of drugs in complex environments, both in-vitro and ex-vivo. The ability to visualize unlabelled compounds inside the cell at physiological dosages can offer valuable insight into the compound behavior both on and off-target.

SiLC-MS is a semi-automated methodology that allows the collection of intracellular contents using a modified CQ1 imaging system developed by Yokowaga. The instrument is equipped with a confocal microscope that allows bright field imaging as well as fluorescence imaging with 4 lasers (405, 488, 561, and 640 nm). Sampling is performed using the tips developed by Professor Masujima (1-4).

In this study, we show the applicability of the SiLC-MS technology to drug discovery, as it is crucial to identify compound and its metabolites when incubated in a mammalian cell at a therapeutic dose. We report on the validation studies performed using the SiLC-MS platform, in these validation studies we assess the ability to distinguish different cell types based on their metabolomic fingerprint, furthermore, we have also evaluated if this assay was sensitive enough to detect drugs intracellularly.

Presenter: Carla Newman, Scientific Leader (Celluar Imaging and Dynamics), GSK

News

Looking for more information on our people, technology and solutions?

Contact Us

Top